【摘要】 目的:对甘肃省水痘疫苗接种进行成本效益分析,为今后制定水痘防控策略提供参考依据。方法:设定三种免疫策略,即未予以免疫接种、策略Ⅰ常规免疫(1岁时接种1剂次水痘疫苗)、策略Ⅱ常规免疫+加强免疫(1岁和12岁各接种1剂次水痘疫苗)、策略Ⅲ常规免疫+强化免疫(2-15岁强化免疫1剂次及1岁接种1剂次水痘),利用EVITA模型评价成本效益,推算15年的水痘发病情况、经济负担、BCR值和NPV值。结果:未予以免疫接种:15年累计发病5 301 764例;策略Ⅰ:BCR=0.744,NPV=-0.98;策略Ⅱ:BCR=0.595,NPV=-6.19;策略Ⅲ:BCR=1.518,NPV=0.49。以策略Ⅲ的BCR值最高,BCR>1且NPV>0,说明该策略可接受,成本效益最好。结论:常规免疫+强化免疫的免疫接种策略是水痘预防控制的最佳方案。更多还原

【Abstract】 Objective: To analyze cost-benefit of Varicella Attenuated Live Vaccine(VarV) immunization in Gansu Province.for varicella prevention and control in the furture.Methods: Three different strategies versus no vaccination were performed.Strategy Ⅰ: Routine Immunization only(one dose in toddlers 1～1.5 years);Strategy Ⅱ: Routine plus Catching-up Immunization(one dose was caught up in adolescents of 12 years);Strategy Ⅲ: Routine plus Supplementary Immunization Activities in children of 2～15 years.EVITA model is used to evaluate cost-benefit and calculate incidence,economical burden,BCR and NPV of Varicella in future 15 years.Result: Accumulated 5 301 764 cases will occur in no vaccination people;Strategy Ⅰ: BCR=0.744,NPV =-0.98;Strategy Ⅱ: BCR=0.595,NPV =-6.19;StrategyⅢ:BCR=1.518,NPV =0.49.BCR of StrategyⅢ is highest and BCR>1&NPV>0,so cost-benefit of StrategyⅢ is the best.Conclusion: Routine plus Supplementary Immunization Activities in children 2～15 years is the best for Varicella control.更多还原